A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients

Published:2016-10 Issue: Volume:40 Page:1-6
ISSN:1094-5539
Container-title:Pulmonary Pharmacology & Therapeutics
language:en
Short-container-title:Pulmonary Pharmacology & Therapeutics

Author:

Singh D.,Leaker B.,Boyce M.,Nandeuil M.A.,Collarini S.,Mariotti F.,Santoro D.,Barnes P.J.

Funder

Chiesi Farmaceutici SpA.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine

Reference24 articles.

1. Localized effects of cAMP mediated by distinct routes of protein kinase A;Tasken;Physiol. Rev.,2004

2. Selective PDE inhibitors as novel treatments for respiratory diseases;Page;Curr. Opin. Pharmacol.,2012

3. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial;Martinez;Lancet,2015

4. Efficacy of roflumilast in the COPD frequent exacerbator phenotype;Wedzicha;Chest,2013

5. Roflumilast for asthma: safety findings from a pooled analysis of ten clinical studies;Chervinsky;Pulm. Pharmacol. Ther.,2015

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhalational Drug Devices: Revisiting the Linchpin of Asthma Management;Journal of Personalized Medicine;2024-08-16

2. Functional rescue of CFTR in rectal organoids from patients carrying R334W variant by CFTR modulators and PDE4 inhibitor Roflumilast;Respiratory Investigation;2024-05

3. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022;Molecules;2022-08-04

4. Novel Therapeutic Strategies in Asthma-Chronic Obstructive Pulmonary Disease Overlap;Immunology and Allergy Clinics of North America;2022-08

5. Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?;Cureus;2022-07-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3